Few data are available on genotype -phenotype interactions among familial hypercholesterolemia (FH) patients in South European populations and there are no data about the influence of R3500Q mutation on lipoprotein phenotype compared to low-density lipoprotein receptor (LDLR) mutations. The objective of the study is to analyze the influence of mutations in the LDLR and apolipoprotein B (apoB) genes on lipoprotein phenotype among subjects clinically diagnosed of FH living in East Spain. In all, 113 FH index patients and 100 affected relatives were studied. Genetic diagnosis was carried out following a protocol based on Southern blot and PCR-SSCP analysis. A total of 118 FH subjects could be classified into three groups according to the type of LDLR mutations (null mutations, missense mutations affecting the ligand binding 3-5 repeat, and missense mutations outside this domain). In addition, the lipoprotein phenotype of these FH groups was compared with 19 heterozygous subjects with familial ligand-defective apoB (FDB), due to R3500Q mutation. FH patients carrying missense mutations affecting the ligand binding repeat 3-5 showed total and LDL cholesterol levels significantly higher than FH patients with missense mutations in other LDLR domains or FDB patients. FH subjects carrying null mutations showed lower high-density lipoprotein cholesterol plasma values compared to FH carrying missense mutations. FDB subjects showed the lowest total and LDL cholesterol plasma values. In conclusion, the type of LDLR gene mutation and R3500Q mutation influences the lipoprotein phenotype of FH population from East Spain.
Introduction
Familial hypercholesterolemia (FH) is an autosomal dominant disease defined at the molecular level by the presence of mutations in the low-density lipoprotein receptor (LDLR) gene and characterized by markedly elevated lowdensity lipoprotein cholesterol (LDLc) levels, tendon xanthomata and increased risk of coronary heart disease (CHD). 1 -4 FH shows great variability in phenotypic expression, which may be influenced by factors such as age, gender, diet, type of LDLR mutations or other genes. 5 -8 The type of LDLR gene mutation has been associated to different phenotype expression, 6, 8, 9 response to statins 10, 11 and risk of premature CHD. 5 In Northern European FH
populations, several studies have demonstrated that the type of mutation in the LDLR gene influences the FH phenotype expression. 12 -15 Affected individuals with LDLR mutations predicted to be severe, such as null mutations or mutations affecting the ligand-binding repeat 3 -5 of the receptor, presented higher plasma levels of total and LDLc. In Southern European FH populations, only Bertolini et al 16 have studied the relationships between the type of LDLR gene mutation and expression of the FH phenotype, as far as we know. These authors have reported that receptor-negative mutations are associated with higher plasma levels of total and LDLc compared to affected subjects with receptor-defective mutations. Altogether, these results suggest that DNA diagnosis could allow the study of genotype -phenotype interactions in terms of estimating the clinical severity and prognosis. When compared with Northern Europeans, Spanish FH subjects present lower levels of plasma LDLc and lower prevalence of tendon xanthomata, 17 making genetic diagnosis even more important. We have previously described large and point mutations in Spanish FH subjects and analyzed the influence of LDLR gene mutation on treatment response in our population. 18 -20 FH subjects carrying large mutations affecting promotor region have higher LDLc plasma values. FH subject carriers of null mutations showed a poorer response to simvastatin treatment than FH carriers of no null mutations. Familial ligand-defective apolipoprotein B (apoB)-100 (FDB) is an autosomal dominant inherited disease due to mutations in the apoB gene. 21 It is characterized by elevated plasma total and LDLc levels and premature CHD. Three mutations (R3500Q, R3500W and R3531C) are mostly responsible for the disease by reducing the binding of LDL particles to the LDLR. 21, 22 The R3500Q mutation was the first described and is the most prevalent, while other point mutations (R3500W and R3531C) are rare causes of FDB. 23, 24 The prevalence of FDB has been estimated to be approximately 1/500 in North America, 22 whereas in Europe seems to be high in the Northwestern part of Switzerland (1/114), Eastern France and Southern Germany 22, 25, 26 and low in Italy and Spain. Miserez et al 27 proposed that FDB emerged from mesolithic ancestors of Celtic people. FDB is clinically indistinguible from FH. However, the plasma LDLc levels in age-matched FDB heterozygotes vary over a wide range and, in some families, heterozygous carriers of the R3500Q mutation show normal LDLc plasma levels. 21, 25 In the Spanish population, we have recently described the first FDB family and predicted a low prevalence of this disease, since only one FDB out of 113 FH index patients was detected. 26 On the contrary, and due to a founder effect in an isolated region of the Valencia province, we have been able to identify seven affected pedigrees and 19 FDB heterozygotes and one homozygote. 28 This has made possible to compare the phenotype of this group of patients with that of FH subjects. The present study was undertaken to evaluate the influence of the LDLR gene mutation type and the R3500Q mutation of the apoB gene on the lipoprotein phenotype in a South European population where few data on this issue were available up to now.
Subjects and methods

Subjects
The study population consisted of a total of 213 clinically diagnosed FH subjects: 113 index patients and 100 affected relatives that had been referred to our Lipid Clinic ( Table 1 ). All subjects were Caucasian and lived in the Valencia region. The institutional ethics committee from our institution approved the protocol and all subjects gave written informed consent to enter the study.
Diagnostic criteria for FH included: plasma levels of total and LDLc above the 95th percentile corrected for both age and sex, 29 Recklinghausen sphygmomanometer in the sitting position and after a 5-min rest. The mean value of three measurements was considered. CHD was diagnosed if there was a documented history of previous myocardial infarction and/or coronary artery bypass surgery, or angioplasty, or history of angina pectoris and alterations in the stress ECG.
One of the clinically defined FH index patients was found to be a carrier of the R3500Q mutation of the apoB gene (1/113 FH index patients), responsible for FDB. 26 Extending the study to seven affected pedigrees, we could identify 19 heterozygotes for the R3500Q mutation and one homozygote. 26, 28 Laboratory methods Measurement of lipids and lipoproteins After a 12 -14 h fast and in basal situation (4 weeks without treatment with drugs that affect lipid metabolism), blood samples were drawn from an antecubital vein in tubes containing EDTA (Vacutainer) and were centrifuged within 4 h. Plasma was stored at 41C for a maximum of 3 days. Cholesterol and triglyceride levels were measured by enzymatic techniques. 30, 31 High-density lipoprotein cholesterol (HDLc) was measured after precipitation of apoB-containing lipoproteins with polyanions, 32 and very-low-density lipoprotein cholesterol (VLDLc) after separation of VLDL (do1.006 g/ ml) by ultracentrifugation. 33 The LDLc was calculated by subtraction of VLDL and HDL cholesterol from total cholesterol (TC). Total plasma apoB was measured by immunoturbimetry. 34 Plasma Lp(a) concentrations were determined by ELISA. 35 The coefficients of variation for lipids and lipoproteins were o5%.
Genetic methods DNA extraction was performed by a standard procedure. Genetic diagnosis of FH was previously established through identification of mutations of LDLR gene by Southern blot analysis 18 and DNA sequencing of abnormal SSCP bands. 20 Screening for the apoB mutations was performed by PCR amplification, as described by Schuster et al, 36 and SSCP analysis; 20 DNA samples carrying the mutations R3480P, R3500Q, R3500W and R3531C, responsible for FDB, were used as controls. Genotyping for the ApoE polymorphisms was performed following the method described by Hixon 
Results
Genetic diagnosis of FH and FDB
The genetic diagnosis of FH was previously established using a three-step protocol that screened mutations at the apoB gene, responsible for FDB, and major rearrangements and minor or point mutations in the LDLR gene, responsible for FH. 18, 20 Only one R3500Q mutation carrier was identified among the 113 FH index patients. 20 The sample was screened for major rearrangements in the LDLR gene by Southern blot analysis. Five rearrangements were detected and characterized, 18 two of them were due to duplications of internal regions of the gene (FH Valencia-2 and FH Valencia-3), whereas the rest were caused by partial deletions, which eliminate the promoter region in two cases (FH Valencia-1 and -5). The mRNA analysis of the alleles with internal rearrangements (FH Valencia-2, -3 and -4) indicated that these resulted in in-frame alterations of the RLDL gene. 18 Thus, FH Valencia-1 and -5 may be classified as null mutations and FH Valencia-2, -3 and -4 as defective mutations. SSCP analysis of the LDLR gene was used to screen for point and minor mutations. A total of 42 minor mutations causing FH were identified; a detailed description of them can be found in a previous report. 20 Effect of LDLR gene and R3500Q mutations on plasma lipids and lipoproteins FH subjects were classified into four groups according to the type of mutation. Group 1 included 45 subjects with null mutations; group 2, 13 subjects with missense mutations affecting ligand binding 3 -5 repeat; group 3, 60 subjects with missense mutation not affecting this domain; and group 4, 19 heterozygotes with the R3500Q mutation in the apoB gene.
Mutations in the LDLR gene were considered null in the case of: (a) major rearrangements deleting the promoter region (FH Valencia-1 and -5), or (b) small mutations producing stop codons (W-18X, E10X, Q133X) or frameshifts in the LDL open reading frame (112insA, 790delAT-GA). Subjects with null mutations included: FH Valencia-1 (n ¼ 4), FH Valencia-5 (n ¼ 8), W-18X (n ¼ 10), E10X (n ¼ 2), Q133X (n ¼ 2), 112insA (n ¼ 15) and 790delATGA (n ¼ 4) (see Figure 1) .
Missense mutations in the exon 4 of the LDLR gene may affect the role of the binding repeat 3 -5 region of the LDLR. The missense mutations used in this study were: C95R (n ¼ 4), E119K (n ¼ 2), P160R (n ¼ 3), D200G (n ¼ 1) and S205P (n ¼ 3) (Figure 1) . Carriers of S156L (n ¼ 5) were not included in this group because this mutation of exon 4 abolishes the binding of LDL, but not that of VLDL, causing only a mild reduction of the receptor function in vitro.
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Missense mutations classified as no affecting the ligand binding repeat 3 -5 region were:
(n ¼ 2) and N804K (n ¼ 2) (see Figure 1) .
Finally, as previously mentioned, group 4 included 19 heterozygotes with the R3500Q mutation, which is responsible of FDB.
Plasma lipid and apoB values at baseline of patients classified according to their respective mutation type are shown in Table 2 . No differences were found between the four groups with respect to age, BMI, gender distribution, presence of CHD, and APOE genotype distribution. Significant differences were observed with respect to TC and LDLc depending on the type of LDLR gene mutation. The mean plasma TC and LDLc levels were significantly higher in subjects with missense mutations affecting the binding repeat 3 -5 domain, whereas the lowest values were found in the FDB group. No statistical differences were found between groups in plasma triglycerides (TG) and VLDL values. HDLc values in the null mutation group were significantly lower than in the missense mutation group. In order to control covariables we have also used the ANCOVA analysis. The intersubjects effect of the type of LDLR mutation on HDLc plasma values was not significantly different (P ¼ 0.66) when BMI was included as covariate and gender as independent variable.
Interestingly, in the whole group, the ANCOVA analysis showed that the type of LDLR mutation (P ¼ 0.006, 0.014), but not age or gender, had an independent influence on TC and LDLc plasma values.
Discussion
This is the second study carried out in a South European FH population aimed to analyze the relationships between the type of mutation affecting genes involved in lipid metabolism (the LDLR and ApoB genes) and phenotype. Our results indicate that the type of LDLR gene mutation has an impact on lipoprotein phenotype. The FH group with missense mutations affecting the binding repeat 3 -5 domain (group 2) presents the highest TC and LDLc plasma concentrations, which determines a significant difference with groups 3 and 4 (Po0.05). However, the TC and LDLc values of the group with null mutations (group 1) were not statistically different than those of the other groups. On the other hand, FDB subjects showed the lowest TC and LDLc plasma values. addressed this issue. They studied 282 FH subjects from Italy, and identified 71 LDLR gene mutations responsible for the disease. Separating the molecularly defined FH subjects into two groups (receptor negative and receptor defective), they showed that FH subjects with receptornegative mutations had higher TC plasma values (18%) and lower HDLc (À5%) than subjects in the receptordefective group. The percentage of xanthomas and CHD in the receptor-negative group was two-fold higher than in the receptor-defective group. All these observations suggest that different mutations of the LDLR gene are associated with differences in plasma lipid levels, although the basis for these differences are not clear. One possible explanation could be that upregulation of the wild-type LDLR allele was affected by the nature of the mutant allele, or that some defective mutations had residual LDLR activities 13, 14 On the other hand, genetic variability due to DNA polymorphisms of the wild type allele could quantitatively influence LDLc concentrations, as has been reported by Bétard et al 38 in French Canadian FH women carrying the French Canadian 10 kb deletion, which may further complicate the interpretation of data. One could expect that null mutations where nonreceptor is expressed and missense mutations affecting the binding domain will correlate with a severe phenotype, compared to other mutations where residual activity or expression of the receptor will be predicted. In contrast to this hypothesis, the results of previous studies 14, 15, 39, 40 indicate that FH patients carrying null mutation not always have the highest TC and LDLc plasma values. In most studies, FH subject carriers of a mutation predicted to be severe (not only null mutations) or that affects five repeat of the binding domain region have the most atherogenic lipid profile (higher plasma values of TC and LDLc). This is consistent with our results. In our study, we have found that FH patients carrying mutations predicted to be severe (null plus missense mutations affecting the binding repeat 3 -5 region) have the worst lipid phenotype (higher plasma values of TC and LDLc and lower HDLc).
The differences found in the revised studies could be explained by methodological differences, selection vias and the classification used for LDLR gene mutations.
We have not found statistically significant differences in TC and LDLc plasma values between the null mutation group (group 1) and the group with missense mutations affecting 3 -5 binding repeat (group 2). Similar results have been previously demonstrated. 14, 15, 40 One possible explanation is that FH patient carriers of null mutations (predicted to be severe) only express the normal receptor in the membrane of their cells. In contrast, FH patient carriers of the missense mutations express both the normal receptor and the altered receptors. This situation could facilitate a local competition between both receptors so that the internalization process could be affected. In addition, in the case of missense mutations affecting the 3 -5 repeat, the situation would worsen, because the affected protein could not bind the apoB.
Another possibility is that, in group 3 (missense mutations not affecting the binding repeat 3 -5 region), we could have included some mutations affecting the binding domain (missense mutations localized in exon 3 and 6), which could increase the average values of TC and LDLc of the entire group.
Finally, we cannot exclude differences in lipid profiles due to the influence of environmental or other genetic factors in our FH population. It should be noted that interaction with other genes 41 47, 48 have demonstrated that FDB subjects have lower total and LDLc plasma values than FH subjects. This is also the case in our study done in a South European population. The explanation for these differences has been attributed to the increased clearance of LDL precursors that has been observed in heterozygous and homozygous FDB patients. 49 There are different possible classifications of FH according to the type of LDLR mutations. 12 -16 An alternative is to classify them into two groups (receptor negative and receptor defective). The problem is that the defective mutations group can include severe or mild mutations, limiting the study of genotype -phenotype relationship in FH subjects. Our study points out, in a South European outbreed FH population, that the type of LDLR mutation and the R3500Q mutation of the apoB gene have an impact on the lipid phenotype expression. In the general population, a direct relationship exists between the magnitude of hypercholesterolemia and prevalence and incidence of CHD, as well as onset of symptoms. Therefore, the differences in TC and LDLc, found between molecularly defined FH subjects, could explain the different risk for CHD observed in these patients. Moreover, Vohl et al 5 and
Bertolini et al 16 have demonstrated that FH subjects carrying a receptor-negative mutation have an increased risk for CHD compared to receptor-defective subjects. In addition, Jansen et al 50 have demonstrated that LDLc plasma values alone could not account for the difference in CHD risk in these FH subjects. We have not found significant differences in CHD prevalence between the groups. This can be attributed to the low number of subjects studied that limited the power of the study to investigate this issue.
Our results and those of others 5, 8, 9, 11, 12, 15, 16 suggest that identification of mutations in the LDLR gene may allow a better assessment of clinical expression in these subjects with high CHD risk. In this sense, prospective studies should be performed to evaluate further the impact of genotype on severity of FH. In addition, the genetic diagnosis and molecular characterisation of LDLR gene mutations will allow a better assessment of response to treatment, prevention and family screening in these subjects.
